Immunotherapy with combination therapy comprising an immunotoxin
AssigneeDuke University
InventorsDarell BIGNER, Vidyalakshmi CHANDRAMOHAN, Ira H. PASTAN
Life of this patent
Estimating the term…
Abstract
Provided is a combination and a method of using combination therapy to treat tumor in an individual. An immunotoxin and an immunostimulator are administered to the individual, wherein the immunotoxin comprises a single chain variable region antibody fused to a PE38 truncated Pseudomonas exotoxin, and the immunostimulator comprises an anti-CD40 agonist antibody. The combination may further comprise a checkpoint inhibitor comprising one or more of an anti-PD-1 antibody and an anti-PD-L1 antibody.
Claims18
A method of treating a solid tumor expressing one or more of EGFRwt and EGFRvIII in an individual, comprising:
- administering to the individual a therapeutically effective amount of an immunotoxin comprising a single chain variable region antibody fused to a Pseudomonas exotoxin comprising PE38, wherein the single chain variable region antibody comprises CDR1, CDR2, and CDR3 regions as shown in SEQ ID NO:
- 1-6;
- and
- administering a therapeutically effective amount of an anti-CD40 agonist antibody to the individual.
A kit for treating a tumor, comprising:
- an immunotoxin comprising a single chain variable region antibody fused to a PE38 truncated Pseudomonas exotoxin, wherein the single chain variable region antibody has CDR1, CDR2, and CDR3 regions as shown in SEQ ID NO:
- 1-6;
- and an anti-CD40 agonist antibody.
A composition comprising an immunotoxin comprising a single chain variable region antibody fused to a PE38 truncated Pseudomonas exotoxin, wherein the single chain variable region antibody has CDR1, CDR2, and CDR3 regions as shown in SEQ ID NO:
- 1-6;
- and an anti-CD40 agonist antibody.
Dependencies are inferred from the claim text.